Mobile app for managing depression in multiple sclerosis patients
Care Technology to Ascertain, Treat, and Engage the Community to Heal Depression in Patients With Multiple Sclerosis: Closing the Gaps in Depression Care for People With MS By Closing the Information Loop
This study tests a mobile app that helps people with multiple sclerosis share their mood changes with their doctors to better manage depression.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | University of California, San Francisco Academic / other |
| Locations | 1 site (San Francisco, California) |
| Trial ID | NCT05865405 on ClinicalTrials.gov |
What this trial studies
This study evaluates the MS CATCH application, a mobile tool designed to enhance communication between patients with multiple sclerosis and their neurologists regarding mood-related symptoms. Patients will regularly report their mood through the app, which will alert their clinician to any concerning changes. The neurologist can access a comprehensive dashboard that integrates patient data and local resources to improve treatment and follow-up care. The approach is based on behavioral change principles and aims to improve the overall management of depression in MS patients.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 to 80 with a diagnosis of multiple sclerosis and mild to moderate depression.
Not a fit: Patients with severe cognitive impairments, psychotic disorders, or other significant central nervous system conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this app could significantly improve the monitoring and treatment of depression in patients with multiple sclerosis.
How similar studies have performed: Other studies have shown promise in using digital health tools for mental health management, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of MS (relapsing or progressive) by 2017 McDonald Criteria18 * Ages 18 to 80 * PHQ-9 score of 5-19 * Any MS therapy, or no treatment * California resident to enable clinical telemedicine visits if warranted during the study visit Exclusion Criteria: * Cognitive dexterity or visual impairment (typically defined as corrected acuity less than 20/70) that, in the opinion of the study neurologist (RB), would put the participant at risk or limit their ability to adhere to the study protocol * Inability to provide informed consent * Psychotic disorders: bipolar disorder, schizophrenia, schizoaffective disorder * Substance abuse that in the treating neurologist's perspective could influence the patient's safety on study or adherence to study protocol * Another co-morbid CNS diagnosis eg. TBI
Where this trial is running
San Francisco, California
- Weill Institute for Neurosciences, University of California, San Francisco — San Francisco, California, United States (Recruiting)
Study contacts
- Principal investigator: Riley Bove, MD — University of California, San Francisco
- Study coordinator: Riley Bove, MD
- Email: riley.bove@ucsf.edu
- Phone: 415.595.2795
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.